Dyadic Applied BioSolutions
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1044 N Us Hwy 1 Ste 201, Jupiter, Florid...Phone Number
(561) 743-8333Website
www.dyadic.comRevenue
<$5 MillionStock Symbol
DYAIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Dyadic Applied BioSolutions
Dyadic International is a global biotechnology company founded in 1979 that develops a biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica, named C1. This innovative technology enables the development and manufacture of low-cost proteins for biologic vaccines and drugs. The C1 platform aims to speed up development, lower production costs, and improve performance of various therapeutic products including virus-like particles, antigens, monoclonal antibodies, and other proteins. Dyadic focuses on research and development collaborations and licensing arrangements to leverage its technologies in biopharmaceutical manufacturing. The company works to bring biologic products to market more efficiently, potentially improving healthcare accessibility through its proprietary fungal expression system.Explore more
Dyadic Applied BioSolutions Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dyadic Applied BioSolutions your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Dyadic Applied BioSolutions is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Dyadic Applied BioSolutions has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Dyadic Applied BioSolutions has new funding data
Dyadic Applied BioSolutions, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Dyadic Applied BioSolutions recently announced quarterly report
Product Launch: Get notified when Dyadic Applied BioSolutions launches new products
Congratulate Masked Content for being promoted to Masked Content at Dyadic Applied BioSolutions
Click to see if Dyadic Applied BioSolutions had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Dyadic Applied BioSolutions
Find 2 more new buyers
Compare Similar Companies to Dyadic Applied BioSolutions
Compare insights from companies similar to Dyadic Applied BioSolutions, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dyadic Applied BioSolutions is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dyadic Applied BioSolutions is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dyadic Applied BioSolutions.
Dyadic Applied BioSolutions financials insights
Gather financial insights about Dyadic Applied BioSolutions, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Dyadic Applied BioSolutions Tech Stack
A closer look at the technologies used by Dyadic Applied BioSolutions
Most Recent Scoops
Person-Based
Partnership
Partnership, Product Development, Product Management, Business Development, Intellectual Property, Legal Affairs, Bioengineering
Project
Dyadic Applied BioSolutions is shifting focus towards non-therapeutic applications for faster revenue generation, driven by shorter time to market, lower regulatory and financial barriers, and the ability to commercialize products in months rather than years.
Product Development, Corporate Strategy
Project
Dyadic Applied BioSolutions News & Media
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine DevelopmentDyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET
Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dyadic Applied BioSolutions
Sign Up For FreeTo access detailed company insights
Dyadic International is a global biotechnology company founded in 1979 that develops a biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica, named C1. This innovative technology enables the development and manufacture of low-cost proteins for biologic vaccines and drugs. The C1 platform aims to speed up dev... Read More
